Logo image of CBLL

CERIBELL INC (CBLL) Stock Fundamental Analysis

NASDAQ:CBLL - Nasdaq - US15678C1027 - Common Stock - Currency: USD

17.74  +0.52 (+3.02%)

After market: 17.74 0 (0%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to CBLL. CBLL was compared to 503 industry peers in the Health Care Equipment & Supplies industry. While CBLL seems to be doing ok healthwise, there are quite some concerns on its profitability. CBLL is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

CBLL had negative earnings in the past year.
CBLL Yearly Net Income VS EBIT VS OCF VS FCFCBLL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

Looking at the Return On Assets, with a value of -18.95%, CBLL is in line with its industry, outperforming 50.80% of the companies in the same industry.
With a Return On Equity value of -22.37%, CBLL perfoms like the industry average, outperforming 58.82% of the companies in the same industry.
Industry RankSector Rank
ROA -18.95%
ROE -22.37%
ROIC N/A
ROA(3y)-36.98%
ROA(5y)N/A
ROE(3y)-55.29%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CBLL Yearly ROA, ROE, ROICCBLL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

CBLL has a better Gross Margin (86.72%) than 97.86% of its industry peers.
CBLL does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 86.72%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CBLL Yearly Profit, Operating, Gross MarginsCBLL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024 0 50 -50 -100

More info and screens

6

2. Health

2.1 Basic Checks

CBLL does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CBLL has been increased compared to 1 year ago.
CBLL has a better debt/assets ratio than last year.
CBLL Yearly Shares OutstandingCBLL Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 10M 20M 30M
CBLL Yearly Total Debt VS Total AssetsCBLL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

CBLL has an Altman-Z score of 11.06. This indicates that CBLL is financially healthy and has little risk of bankruptcy at the moment.
CBLL has a Altman-Z score of 11.06. This is amongst the best in the industry. CBLL outperforms 89.84% of its industry peers.
A Debt/Equity ratio of 0.11 indicates that CBLL is not too dependend on debt financing.
CBLL has a Debt to Equity ratio of 0.11. This is comparable to the rest of the industry: CBLL outperforms 58.82% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.11
Debt/FCF N/A
Altman-Z 11.06
ROIC/WACCN/A
WACC9.12%
CBLL Yearly LT Debt VS Equity VS FCFCBLL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 50M 100M 150M

2.3 Liquidity

A Current Ratio of 17.36 indicates that CBLL has no problem at all paying its short term obligations.
With an excellent Current ratio value of 17.36, CBLL belongs to the best of the industry, outperforming 98.40% of the companies in the same industry.
A Quick Ratio of 16.81 indicates that CBLL has no problem at all paying its short term obligations.
The Quick ratio of CBLL (16.81) is better than 98.40% of its industry peers.
Industry RankSector Rank
Current Ratio 17.36
Quick Ratio 16.81
CBLL Yearly Current Assets VS Current LiabilitesCBLL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 50M 100M 150M 200M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for CBLL have decreased strongly by -30.29% in the last year.
The Revenue has grown by 44.71% in the past year. This is a very strong growth!
EPS 1Y (TTM)-30.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)44.71%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

CBLL is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.81% yearly.
Based on estimates for the next years, CBLL will show a very strong growth in Revenue. The Revenue will grow by 31.71% on average per year.
EPS Next Y29.65%
EPS Next 2Y15.38%
EPS Next 3Y15.81%
EPS Next 5YN/A
Revenue Next Year33.98%
Revenue Next 2Y31.29%
Revenue Next 3Y31.71%
Revenue Next 5YN/A

3.3 Evolution

CBLL Yearly Revenue VS EstimatesCBLL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 2027 50M 100M
CBLL Yearly EPS VS EstimatesCBLL Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 -0.5 -1 -1.5 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CBLL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CBLL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CBLL Price Earnings VS Forward Price EarningsCBLL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CBLL Per share dataCBLL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

CBLL's earnings are expected to grow with 15.81% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.38%
EPS Next 3Y15.81%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CBLL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CERIBELL INC

NASDAQ:CBLL (6/17/2025, 5:49:07 PM)

After market: 17.74 0 (0%)

17.74

+0.52 (+3.02%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-08 2025-05-08/amc
Earnings (Next)N/A N/A
Inst Owners69.7%
Inst Owner Change4.65%
Ins Owners10.51%
Ins Owner Change11.36%
Market Cap641.12M
Analysts86.67
Price Target32.9 (85.46%)
Short Float %3.78%
Short Ratio2.82
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-3.35%
Min EPS beat(2)-23.32%
Max EPS beat(2)16.63%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)3.94%
Min Revenue beat(2)3.52%
Max Revenue beat(2)4.36%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-2.27%
PT rev (3m)-3.01%
EPS NQ rev (1m)1.23%
EPS NQ rev (3m)7.91%
EPS NY rev (1m)0%
EPS NY rev (3m)-31.71%
Revenue NQ rev (1m)0.02%
Revenue NQ rev (3m)2.41%
Revenue NY rev (1m)0%
Revenue NY rev (3m)2.8%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 9.8
P/FCF N/A
P/OCF N/A
P/B 3.54
P/tB 3.54
EV/EBITDA N/A
EPS(TTM)-1.13
EYN/A
EPS(NY)-1.5
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS1.81
BVpS5.01
TBVpS5.01
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -18.95%
ROE -22.37%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 86.72%
FCFM N/A
ROA(3y)-36.98%
ROA(5y)N/A
ROE(3y)-55.29%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.31
Health
Industry RankSector Rank
Debt/Equity 0.11
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 17.36
Quick Ratio 16.81
Altman-Z 11.06
F-ScoreN/A
WACC9.12%
ROIC/WACCN/A
Cap/Depr(3y)209.9%
Cap/Depr(5y)N/A
Cap/Sales(3y)3.91%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-30.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y29.65%
EPS Next 2Y15.38%
EPS Next 3Y15.81%
EPS Next 5YN/A
Revenue 1Y (TTM)44.71%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year33.98%
Revenue Next 2Y31.29%
Revenue Next 3Y31.71%
Revenue Next 5YN/A
EBIT growth 1Y-32.18%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-38.21%
EBIT Next 3Y8.11%
EBIT Next 5YN/A
FCF growth 1Y-18.49%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-20.18%
OCF growth 3YN/A
OCF growth 5YN/A